FIELD: biotechnology.;SUBSTANCE: invention relates to peptide antagonists of calcitonin gene-related peptide (CGRP), and can be used in medicine for treatment of a condition associated with elevated levels of CGRP, including migraine. A peptide with a structure X1- Y1- Z1 structure is proposed, where X1 has the X11-X12-X13-X14-X15-X16-X17 structure (SEQ ID #16), where X17 is Cys, where X11 is selected from the group consisting of Ala, Cys and Gly, and where X12 is selected from the group consisting of Cys and Ser, provided that one of X11 or X12 is Cys, where X13 is selected from the group consisting of Arg, Asn, Asp and Val, where X14 is selected from the group consisting of Leu, Phe and Thr, where X15 is selected from the group consisting of Ala, Gly and Ser, where X16 is selected from the group consisting of Ala, Ile, Leu, Ser, and Val. At that, Y1 is Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID #34); and Z1 is Val-Gly-Ser-Lys-Ala-Phe-NH2 (SEQ ID #46).;EFFECT: obtaining of an effective antagonist for CGRP.;23 cl, 7 tbl, 1 ex
展开▼